Drugs / tretazicar
tretazicar
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04374240 | Mar 2013 → Aug 2021 | prostate cancer | University of Birmingham | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00746590 | Sep 2008 → Jun 2009 | hepatocellular carcinoma | BTG International Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tretazicar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00746590 ↗ |
| Known as | CB1954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04374240 ↗ |
| Known as | NSC-115829 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23330 ↗ |
| Modality | Small molecule | — CHEMBL23330 ↗ |
| Route | Intravenous | “administered intravenously” NCT00746590 ↗ |